Investors & Media

Overview

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders.

Investor Inquiries: ir@sagerx.com
Media Inquiries: media@sagerx.com
NASDAQ: SAGE
$ 62.90 0.00 (0.00%)
Day High: N/A
Day Low:  N/A
Volume:    N/A
4:00 PM ET on
Sep 22, 2017

Delayed ~20 min., by eSignal.